News

MedPage Today on MSN6d
IgA Nephropathy Drug With Novel Mechanism Wins FDA Approval
The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...
Investor's Business Daily on MSN5d
Novartis Has A Slight Edge On Travere — Why Analysts Aren't Worried
Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.
MPR2d
Vanrafia Gets Accelerated Approval for Immunoglobulin A Nephropathy
The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...
pharmaphorum6d
Novartis gets FDA nod for second of three IgAN drugs
Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...
PMLive5d
Novartis’ Vanrafia granted FDA approval for rare kidney disease IgA nephropathy
Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...
PharmExec5d
FDA Approves Novartis’ Vanrafia for Primary Immunoglobulin A Nephropathy
Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...
The American Journal of Managed Care5d
FDA Approves Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy
Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...
Medical Dialogues4d
FDA Grants Accelerated Approval to Atrasentan for IgA Nephropathy
The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...
Seeking Alpha6d
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA ...
"My son was diagnosed with IgA nephropathy long before there were ... care for this disease," said Victor Bultó, President, US, Novartis. "Building on our longstanding legacy in nephrology ...
Medical Dialogues6d
Novartis receives USFDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy
Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia (atrasentan), a potent ...
Emerging IgAN Therapies Bring Hope – But Patients Still Face Emotional and Financial Barriers, According to Spherix Global Insights
Spherix Global Insights has released the first edition of its new Patient Dynamix™: IgA Nephropathy (US) series, delivering a comprehensive look at the IgAN patient journey amid a rapidly evolving ...
KXAN6d
Novartis receives FDA accelerated approval for Vanrafia®
"My son was diagnosed with IgA nephropathy long before there were ... care for this disease," said Victor Bultó, President, US, Novartis. "Building on our longstanding legacy in nephrology ...